The covid CR was a master stroke IMO, keep that gravy train chooing.
And what is to show from the Covid CR?
Well:
- One slide in the presso, outling nothing on the sales front (just another director to pay)
- a bump in diagnostic revenue from 100k FY19 to 200k FY20
- 30 something thousand dollars worth of diagnostic goods at cost in inventory
So I guess the "and working capital" caveat came into play real hard.
Shareholders deserve better
The covid CR was a master stroke IMO, keep that gravy train...
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| AN1 (ASX) Chart |
Day chart unavailable